Programme Overview

In order to help busy clinicians and oncology healthcare professionals understand the emerging data which will aid future management of their patients, this Symposium will review the latest data for metastatic breast cancer (mBC) driven by HER2 and the clinical implications of emerging data in the metastatic setting.

Over the past three decades, successive generations of monoclonal antibodies (mAb), antibody drug conjugates (ADC) and small molecule tyrosine kinase inhibitors targeting HER2 have been developed, and in mBC driven by HER2, use of these targeted treatments has significantly improved outcomes for patients. Yet, despite these advances, there remain clear unmet needs for greater efficacy and improved safety that still need to be addressed.

As we begin a new decade, this Symposium will evaluate recently presented data in the HER2 positive metastatic breast cancer setting and consider how this data may impact future clinical practice as assessed by the ESMO Magnitude of Clinical Benefit Scale (MCBS) in the context of the benefit-risk profiles. The Symposium will conclude with a panel discussion session and the opportunity to address questions from the audience.

Faculty

Javier Cortes, MD
Vall D’Hebron Institute of Oncology, Barcelona, Spain

Sandra Swain, MD
Georgetown University Medical Center, Washington DC, USA

Fatima Cardoso, MD
Champalimaud Clinical Center, Lisbon, Portugal